Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | P-PSMA-101 CAR-T cells |
Synonyms | |
Therapy Description |
P-PSMA-101 CAR-T cells are T-cells that express a chimeric antigen receptor targeting PSMA, which potentially enhances anti-tumor immune response against PSMA-expressing tumor cells and reduces tumor burden (Cancer Res 2018;78(16 Suppl):Abstract nr A071). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
P-PSMA-101 CAR-T cells | PSMA CARTyrin | P-PSMA-101 CAR-T cells are T-cells that express a chimeric antigen receptor targeting PSMA, which potentially enhances anti-tumor immune response against PSMA-expressing tumor cells and reduces tumor burden (Cancer Res 2018;78(16 Suppl):Abstract nr A071). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04249947 | Phase I | P-PSMA-101 CAR-T cells Rimiducid | P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) | Active, not recruiting | USA | 0 |